Celldex Therapeutics vs Lisata Therapeutics
Celldex Therapeutics is the larger business, with $1.5m of revenue in fiscal 2025 against $170,000 for Lisata Therapeutics (9.1 times as much). Celldex Therapeutics grew faster (-78.0% against -83.0%). Lisata Therapeutics kept more of each dollar of sales as profit: a net margin of -9756.5% against -16748.0%. Celldex Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Celldex TherapeuticsCLDX, 2025 | Lisata TherapeuticsLSTA, 2025 |
|---|---|---|
| Revenue | $1.5m | $170,000 |
| Revenue growth | -78.0% | -83.0% |
| Net income | −$259m | −$16.6m |
| Operating margin | -18599.8% | -10711.2% |
| Net margin | -16748.0% | -9756.5% |
| Return on equity | -40.6% | -74.7% |
| Free cash flow | −$214m | −$16.0m |
| Cash | $28.9m | $16.0m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 198 | 21 |
| Market value | $2.32bn | $9.8m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 5 (Weak) |
| Insider trades, 12 months | 0 buys, 2 sales | 0 buys, 0 sales |